Nexus Energy Services, Inc. (IBGR)

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2018	FY 2017
Period Ending	Mar 31, 2019	Sep 30, 2018	Sep 30, 2017
Revenue	-	-	0
Gross Profit	-0.02	-	0
Selling, General & Admin	0.03	0	0
Operating Expenses	0.04	0.01	0.01
Operating Income	-0.06	-0.01	-0.01
Other Non Operating Income (Expenses)	-0	-0	-0
EBT Excluding Unusual Items	-0.06	-0.01	-0.01
Other Unusual Items	0.04	0.15	-
Pretax Income	-0.03	0.14	-0.01
Net Income	-0.03	0.14	-0.01
Net Income to Common	-0.03	0.14	-0.01
Shares Outstanding (Basic)	140	290	290
Shares Outstanding (Diluted)	140	290	290
EPS (Basic)	-0.00	0.00	-0.00
EPS (Diluted)	-0.00	0.00	-0.00
Gross Margin	-	-	100.00%
Operating Margin	-	-	-27860.00%
Profit Margin	-	-	-27970.00%
EBITDA	-0.06	-0	-0
D&A For EBITDA	0.01	0.01	0.01
EBIT	-0.06	-0.01	-0.01
Revenue as Reported	-	-	0

Updated May 20, 2021. Source: S&P Global Market Intelligence. Standard template. Financial Sources.